SAN DIEGO – Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the appointment of Charles P. Slacik to its board of directors, effective June 15, 2011.

Mr. Slacik has served as chief financial officer and senior vice president of Finance for Beckman Coulter since October 2006. He is currently responsible for all aspects of financial management and information technology for Beckman Coulter.

Prior to joining Beckman Coulter, Mr. Slacik was executive vice president and chief financial officer at Watson Pharmaceuticals, a specialty pharmaceutical company in Corona, California. Before that, he served as senior vice president and chief financial officer at C.R. Bard, Inc., which develops and manufactures medical technologies in the fields of vascular, urology, oncology and surgical specialty products. Mr. Slacik earned a Bachelor of Science degree in accounting and finance from the University of Connecticut and is a Certified Public Accountant. He is currently a member of the Orange County Chapter of Financial Executives International and the Connecticut Society of CPAs.

“We are pleased that Charles has agreed to join our board of directors and welcome his contribution as we head into an exciting era for the company,” said Dr. Harry F. Hixson, Sequenom’s CEO. “His years of experience in the healthcare industry and strong business background make him a key addition to our team.”

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM)is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding an exciting era for Sequenom and Sequenom’s commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the collaborative efforts of other parties, Sequenom’s ability to develop and commercialize new technologies and products, particularly new technologies such as diagnostics and laboratory developed tests, Sequenom’s ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in Sequenom, Inc.’s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

SOURCE Sequenom, Inc.